F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.
Industries BiotechnologyGeneticsHealth CareMedicalPharmaceuticalHeadquarters Regions Europe, Middle East, and Africa (EMEA) Founded Date 1998 Founders David Denning Operating Status Active Last Funding Type Private Equity Legal Name F2G Ltd.
Company Type For Profit
Contact Email contact@f2g.com Phone Number 44 (0)161 785 1270
F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversified
into chemistry-driven discovery. They have also assembled an experienced development capacity.